Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196422 | 1.00 | SLC10A2 (0.75) | SLC10A2 | |
| SCHEMBL12196426 | 1.00 | SLC10A2 (0.75) | SLC10A2 | |
| SCHEMBL12196428 | 1.00 | SLC10A2 (0.75) | SLC10A2 | |
| SCHEMBL1361679 | 0.89 | SLC10A2 (0.78) | SLC10A2 | |
| SCHEMBL6221311 | 0.87 | SLC10A2 (0.86) | SLC10A2 | |
| SCHEMBL12196590 | 0.87 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL6827664 | 0.87 | SLC10A2 (0.81) | SLC10A2 | |
| SCHEMBL19789879 | 0.87 | SLC10A2 (0.66) | SLC10A2 | |
| SCHEMBL12196461 | 0.87 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL13619896 | 0.87 | SLC10A2 (0.66) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282991-B1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-8461312-B2 | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-8461312-B2 | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2009132832-A2 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | BBOX1, SULT1E1, PTGS1 | SLC10A2 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.